By Michael Erman and Manas Mishra (Reuters) -Bristol Myers Squibb on Friday agreed to buy Karuna Therapeutics (NASDAQ:) for $14 billion, gaining a promising
Investment Thesis Simultaneously incorporating into your investment portfolio one company that offers a relatively attractive Dividend Yield and one that provides dividend growth brings